- Home
- AMSF vs ASMB Comparison
AMSF vs ASMB Comparison
Compare AMSF & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMSF | ASMB |
|---|---|---|
| Founded | 1985 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Accident &Health Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 519.4M | 512.1M |
| IPO Year | 1996 | 2010 |
Fundamental Metrics
Financial Performance| Metric | AMSF | ASMB |
|---|---|---|
| Price | $24.87 | $25.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $46.33 | $44.20 |
| AVG Volume (30 Days) | ★ 334.3K | 286.9K |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 8.61% | N/A |
| EPS Growth | N/A | ★ 91.78 |
| EPS | ★ 1.21 | N/A |
| Revenue | ★ $317,252,000.00 | N/A |
| Revenue This Year | $8.45 | N/A |
| Revenue Next Year | $6.03 | $638.39 |
| P/E Ratio | $20.43 | ★ N/A |
| Revenue Growth | ★ 2.66 | N/A |
| 52 Week Low | $24.11 | $20.23 |
| 52 Week High | $45.00 | $39.71 |
Technical Indicators
Market Signals| Indicator | AMSF | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 30.00 | 32.91 |
| Support Level | N/A | $25.86 |
| Resistance Level | $34.15 | $30.26 |
| Average True Range (ATR) | 0.59 | 1.89 |
| MACD | 0.07 | -1.21 |
| Stochastic Oscillator | 26.95 | 6.84 |
Price Performance
Historical ComparisonAbout AMSF AMERISAFE Inc.
AMERISAFE Inc is a specialty provider of workers' compensation insurance focused on small to mid-sized employers engaged in hazardous industries, principally construction, trucking, logging and lumber, agriculture, manufacturing, maritime, and telecommunications. The company generates a majority of its revenue in the form of premiums. The Company operates as a single reportable segment, Insurance Operations.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.